Author: Oncotarget

Histology image of flame shaped plasma cells promoting multiple myeloma condition understanding

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the U.S.

April 29, 2026

“Multiple myeloma (MM), the second most common hematologic malignancy in the United States, has undergone transformative therapeutic innovation over the past five decades.” BUFFALO, NY - April 29, 2026 –… read more

Oncotarget

Epigenetic Dysregulation of PDX1 Drives Prostate Cancer Progression

April 15, 2026

“Aberrant DNA methylation changes lead to abnormal gene expression that contributes to the development and progression of prostate cancer (PCa).” BUFFALO, NY - April 15, 2026 – A new research… read more

worried female doctor holding diagnosis and consulting upset senior woman with cancer in hospital

Oncotarget

Cancer Care in Conflict Zones Remains Critically Neglected

April 13, 2026

“Cancer is an escalating yet neglected health crisis among refugees, migrants, and populations affected by conflict.” BUFFALO, NY - April 13, 2026 – A new review was published in Volume… read more

Oncotarget

Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency

April 10, 2026

“Scientific integrity is a crucial component of scholarly publishing.” BUFFALO, NY - April 10, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on April 8, 2026, titled “Oncotarget: Past,… read more

Oncotarget

Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers

April 7, 2026

“Programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are widely used in cancer treatment.” BUFFALO, NY - April 7, 2026 – A new research paper was published… read more

Oncotarget

Bibliometric Mapping Reveals the Evolution of Glioma Classification Research

April 6, 2026

“The findings indicate that the subset of articles focusing on glioma classification that incorporate social factors is relatively scarce in the analyzed data, in contrast to the prominence of epigenetic… read more

Oncotarget

The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells

March 31, 2026

“Aramchol and metformin interacted to modestly enhance cell death in PDX UM cells, though this was less than that caused by the combination of aramchol and the multi-kinase inhibitor regorafenib.”… read more

Oncotarget

CREB5 Linked to Stem Cell-Like Programs That Promote Prostate Cancer Progression

March 24, 2026

“We determined that CREB5 is a key regulator of basal and SCL transcriptional programs and tumor-forming phenotypes in PC.” BUFFALO, NY - March 24, 2026 – A new research paper… read more

Oncotarget

Impact Journals to Participate at AACR Annual Meeting 2026 in San Diego

March 16, 2026

Conference attendees are warmly invited to visit Booth 3641 to meet members of the Impact Journals team, discover notable recent publications, and discuss opportunities for collaboration. BUFFALO, NY – March… read more

Oncotarget

Next-Generation CAR-T Designs That Could Transform Cancer Treatment

February 25, 2026

“CAR T-cell therapy has emerged as a particularly promising cancer-specific treatment strategy.” BUFFALO, NY - February 25, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget… read more